Mark Hollywood
Chief Tech/Sci/R&D Officer bei ZYMEWORKS INC.
Profil
Mark Hollywood is currently the EVP & Head-Technical & Manufacturing Operations at Zymeworks BC, Inc. and the EVP, Head-Technical & Manufacturing Operations at Zymeworks, Inc. Previously, he worked as the Director-Quality Assurance & Quality Control at CellCyte Genetics Corp.
and as the Vice President & Head-ZymoGenetics at Bristol Myers Squibb Co. He obtained his undergraduate degree from Western Illinois University.
Aktive Positionen von Mark Hollywood
| Unternehmen | Position | Beginn |
|---|---|---|
| ZYMEWORKS INC. | Chief Tech/Sci/R&D Officer | 01.01.2019 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 30.04.2019 |
Ehemalige bekannte Positionen von Mark Hollywood
| Unternehmen | Position | Ende |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2019 |
| CELLCYTE GENETICS CORPORATION | Corporate Officer/Principal | - |
Ausbildung von Mark Hollywood
| Western Illinois University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ZYMEWORKS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
CellCyte Genetics Corp.
 CellCyte Genetics Corp. Miscellaneous Commercial ServicesCommercial Services CellCyte Genetics Corp. engaged in the discovery and development of stem cell therapeutic products. It enabled therapeutic advancements to safely deliver stem cells through the patient's own circulatory or vascular system directly into a specific diseased, damaged or dying organ. The company was founded on March 9, 2004 and was headquartered in Freeland, WA. | Commercial Services |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
